Cellectar Biosciences, Inc. (CLRB)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. ( CLRB ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Officer Conference Call Participants Anne Marie Fields Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025.
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Chad J. Kolean - VP, CFO & Secretary James V.
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie Fields - IR, Managing Director, Precision AQ Conference Call Participants Aydin Huseynov - Ladenburg Thalmann Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and Chief Executive Officer Chad Kolean – Chief Financial Officer Jarrod Longcor – Chief Operating Officer Conference Call Participants Jonathan Aschoff – ROTH Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
On Tuesday, Cellectar Biosciences, Inc. CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer.
